805292

Pfizer Inc. — FEI 2416101

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
October 15, 2012
Fiscal Year
2013
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
New York, NY (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
672821 CFR 314.80(b)Failure to review ADE information
673021 CFR 314.80(b)Failure to develop written procedures
673221 CFR 314.80(c)(1)(i)Late submission of 15-day report
673521 CFR 314.80(c)(1)(ii)Failure to investigate serious, unexpected events
673621 CFR 314.80(c)(1)(ii)Submission of report follow-up
682321 CFR 314.80(c)Failure by applicant to report ADE
682521 CFR 314.80(c)(1)(iii)Non-applicant reports to applicant
682921 CFR 314.80(c)(2)Failure to report non-alert ADEs
683121 CFR 314.80(c)(2)Late submission of quarterly safety reports
683221 CFR 314.80(c)(2)Late submission of annual safety reports
684221 CFR 314.80(j)Failure to maintain records